Reply to M. Nishino [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Hodi, Wolchok Tags: CORRESPONDENCE Source Type: research
Pseudoprogression and Measurement Variability [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Nishino Tags: CORRESPONDENCE Source Type: research
Talking to Children With Cancer: Sometimes Less Is More [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Korones Tags: End of life issues, Patient communication, All Art of Oncology Articles Source Type: research
Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials? [STATISTICS IN BRIEF]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: AHern Tags: Clinical Trials, Statistics in Oncology STATISTICS IN BRIEF Source Type: research
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline [ASCO SPECIAL ARTICLE]
Purpose
To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
Methods
The Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature.
Results
Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytored...
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Wright, Bohlke, Armstrong, Bookman, Cliby, Coleman, Dizon, Kash, Meyer, Moore, Olawaiye, Oldham, Salani, Sparacio, Tew, Vergote, Edelson Tags: ASCO Guidelines, Epidemiology, Diagnosis & Staging, Surgery, Chemotherapy ASCO SPECIAL ARTICLE Source Type: research
MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents [BIOLOGY OF NEOPLASIA]
Conclusion
A novel MEF2D-BCL9 fusion we identified characterizes a novel subset of pediatric ALL, predicts poor prognosis, and may be a candidate for novel molecular targeting. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Suzuki, Okuno, Kawashima, Muramatsu, Okuno, Wang, Kataoka, Sekiya, Hamada, Murakami, Kojima, Narita, Narita, Sakaguchi, Sakaguchi, Yoshida, Nishio, Hama, Takahashi, Kudo, Kato, Kojima Tags: Translational Oncology, Acute Lymphoblastic Leukemia BIOLOGY OF NEOPLASIA Source Type: research
Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium [REVIEW ARTICLE]
Conclusion
The harmonized set of POI surveillance recommendations is intended to be scientifically rigorous, to positively influence health outcomes, and to facilitate the care for female survivors of CAYA cancer. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: van Dorp, Mulder, Kremer, Hudson, van den Heuvel-Eibrink, van den Berg, Levine, van Dulmen-den Broeder, di Iorgi, Albanese, Armenian, Bhatia, Constine, Corrias, Deans, Dirksen, Gracia, Hjorth, Kroon, Lambalk, Landier, Levitt, Leiper, Meacham, Mussa, Negge Tags: Non-ASCO Guidelines, Long Term Survival & Late Effects REVIEW ARTICLE Source Type: research
How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer [Surgical Oncology]
Conclusion
To our knowledge, our study provides the first empirically based estimates of occult nodal disease risk in patients after surgery for papillary thyroid cancer as a function of primary tumor stage and number of LNs examined. Our estimates provide an objective guideline for evaluating adequacy of LN yield for surgeons and pathologists in the treatment of papillary thyroid cancer, and especially intermediate-risk disease, for which use of adjuvant radioactive iodine and surveillance intensity are not currently standardized. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Robinson, Thomas, Dinan, Roman, Sosa, Hyslop Tags: Bioinformatics, Prognostic Studies, Diagnosis & Staging, Surgery, Diagnosis & Staging, Surgery Surgical Oncology Source Type: research
Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality [Hematologic Malignancy]
Conclusion
Pretransplantation Mog was significantly associated with an increased risk of GVHD-related mortality, which supports the relevance of CCR4-expressing Tregs after allo-HSCT in humans. In clinical practice, Mog should be cautiously used for patients with ATLL who are eligible for allo-HSCT. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Fuji, Inoue, Utsunomiya, Moriuchi, Uchimaru, Choi, Otsuka, Henzan, Kato, Tomoyose, Yamamoto, Kurosawa, Matsuoka, Yamaguchi, Fukuda Tags: Lymphoma Hematologic Malignancy Source Type: research
Behavioral, Social, and Emotional Symptom Comorbidities and Profiles in Adolescent Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study [Pediatric Oncology]
Conclusion
Behavioral, emotional, and social symptoms frequently co-occur in adolescent survivors of childhood cancer and are associated with treatment exposures and physical late effects. Assessment and consideration of symptom profiles are essential for directing appropriate mental health treatment for adolescent survivors. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Brinkman, Li, Vannatta, Marchak, Lai, Prasad, Kimberg, Vuotto, Di, Srivastava, Robison, Armstrong, Krull Tags: Long Term Survival & Late Effects Pediatric Oncology Source Type: research
Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History [Breast Cancer]
Conclusion
Adolescent girls from BRCA1/2-positive and breast cancer families have higher self-esteem and do not have poorer psychosocial adjustment than peers. However, they do experience greater breast cancer–specific distress and perceived risk of breast cancer, particularly among older girls. Understanding the impact is important to optimize responses to growing up in families at familial and genetic risk for breast cancer, particularly given the debate over the genetic testing of children for cancer susceptibility in adulthood. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Bradbury, Patrick-Miller, Schwartz, Egleston, Henry-Moss, Domchek, Daly, Tuchman, Moore, Rauch, Shorter, Karpink, Sands Tags: Behavioral and Lifestyle Risk Factors Breast Cancer Source Type: research
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 [Breast Cancer]
Conclusion
CM maintenance did not produce a significant reduction in DFS events in hormone receptor–negative early breast cancer. The trend toward benefit observed in the TN, node-positive subgroup supports additional exploration of this strategy in the TN, higher-risk population. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Colleoni, Gray, Gelber, Lang, Thurlimann, Gianni, Abdi, Gomez, Linderholm, Puglisi, Tondini, Kralidis, Eniu, Cagossi, Rauch, Chirgwin, Gelber, Regan, Coates, Price, Viale, Goldhirsch Tags: Chemotherapy Breast Cancer Source Type: research
Efficacy of Mindfulness-Based Cognitive Therapy on Late Post-Treatment Pain in Women Treated for Primary Breast Cancer: A Randomized Controlled Trial [Breast Cancer]
Conclusion
MBCT showed a statistically significant, robust, and durable effect on pain intensity, indicating that MBCT may be an efficacious pain rehabilitation strategy for women treated for breast cancer. In addition, the effect on neuropathic pain, a pain type reported by women treated for breast cancer, further suggests the potential of MBCT but should be considered preliminary. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Johannsen, OConnor, OToole, Jensen, Hojris, Zachariae Tags: Quality of Life, Pain Control, Supportive Care Breast Cancer Source Type: research
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer [Thoracic Oncology]
Conclusion
Our results indicate the better efficacy of crizotinib in patients with ALK variant 1 versus non–variant 1. The ALK variant status might affect the efficacy of ALK-TKIs. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Yoshida, Oya, Tanaka, Shimizu, Horio, Kuroda, Sakao, Hida, Yatabe Tags: Chemotherapy Thoracic Oncology Source Type: research
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer [Rapid Communication]
Conclusion
In this retrospective analysis, patients positive for T790M in plasma have outcomes with osimertinib that are equivalent to patients positive by a tissue-based assay. This study suggests that, upon availability of validated plasma T790M assays, some patients could avoid a tumor biopsy for T790M genotyping. As a result of the 30% false-negative rate of plasma genotyping, those with T790M-negative plasma results still need a tumor biopsy to determine presence or absence of T790M. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Oxnard, Thress, Alden, Lawrance, Paweletz, Cantarini, Yang, Barrett, Janne Tags: Rapid Communications, Translational Oncology Source Type: research
